T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Cervical Cancer|Renal Cancer|Urothelial Cancer|Melanoma|Breast Cancer
Interventions: BIOLOGICAL: Anti-MAGE-A3-DP4 T Cell Receptor (TCR) Peripheral Blood Lymphocytes (PBL)|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: Aldesleukin
Sponsor: National Cancer Institute (NCI)